The Opposing Transcriptional Activities of the Two Isoforms of the Human Progesterone Receptor Are Due to Differential Cofactor Binding

ABSTRACT The human progesterone receptor (PR) exists as two functionally distinct isoforms, hPRA and hPRB. hPRB functions as a transcriptional activator in most cell and promoter contexts, while hPRA is transcriptionally inactive and functions as a strong ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity. Although the precise mechanism of hPRA-mediated transrepression is not fully understood, an inhibitory domain (ID) within human PR, which is necessary for transrepression by hPRA, has been identified. Interestingly, although ID is present within both hPR isoforms, it is functionally active only in the context of hPRA, suggesting that the two receptors adopt distinct conformations within the cell which allow hPRA to interact with a set of cofactors that are different from those recognized by hPRB. In support of this hypothesis, we identified, using phage display technology, hPRA-selective peptides which differentially modulate hPRA and hPRB transcriptional activity. Furthermore, using a combination of in vitro and in vivo methodologies, we demonstrate that the two receptors exhibit different cofactor interactions. Specifically, it was determined that hPRA has a higher affinity for the corepressor SMRT than hPRB and that this interaction is facilitated by ID. Interestingly, inhibition of SMRT activity, by either a dominant negative mutant (C'SMRT) or histone deacetylase inhibitors, reverses hPRA-mediated transrepression but does not convert hPRA to a transcriptional activator. Together, these data indicate that the ability of hPRA to transrepress steroid hormone receptor transcriptional activity and its inability to activate progesterone-responsive promoters occur by distinct mechanisms. To this effect, we observed that hPRA, unlike hPRB, was unable to efficiently recruit the transcriptional coactivators GRIP1 and SRC-1 upon agonist binding. Thus, although both receptors contain sequences within their ligand-binding domains known to be required for coactivator binding, the ability of PR to interact with cofactors in a productive manner is regulated by sequences contained within the amino terminus of the receptors. We propose, therefore, that hPRA is transcriptionally inactive due to its inability to efficiently recruit coactivators. Furthermore, our experiments indicate that hPRA interacts efficiently with the corepressor SMRT and that this activity permits it to function as a transdominant repressor.

[1]  Elisabeth Scheer,et al.  Distinct classes of transcriptional activating domains function by different mechanisms , 1990, Cell.

[2]  B. Katzenellenbogen,et al.  Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors , 1995, Molecular and cellular biology.

[3]  P Chambon,et al.  Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.

[4]  D. Edwards,et al.  The Steroid Receptor Coactivator-1 Contains Multiple Receptor Interacting and Activation Domains That Cooperatively Enhance the Activation Function 1 (AF1) and AF2 Domains of Steroid Receptors* , 1998, The Journal of Biological Chemistry.

[5]  J. Trapman,et al.  Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). , 1998, Molecular endocrinology.

[6]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[7]  D P McDonnell,et al.  Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. , 1993, Molecular endocrinology.

[8]  K. Horwitz,et al.  Nuclear receptor coactivators and corepressors. , 1996, Molecular endocrinology.

[9]  C. Glass,et al.  Nuclear receptor coactivators. , 2000, Advances in pharmacology.

[10]  N. Weigel,et al.  The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor , 1998, Molecular and Cellular Biology.

[11]  D. Toft,et al.  Purification of unactivated progesterone receptor and identification of novel receptor-associated proteins. , 1990, The Journal of biological chemistry.

[12]  L. Chin,et al.  Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression , 1997, nature.

[13]  D. McDonnell,et al.  The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells , 1994, Molecular and cellular biology.

[14]  H. Gronemeyer,et al.  A limiting factor mediates the differential activation of promoters by the human progesterone receptor isoforms. , 1992, The Journal of biological chemistry.

[15]  J. Trapman,et al.  Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. , 1997, Biochemistry.

[16]  D. Edwards,et al.  Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. , 1999, Molecular endocrinology.

[17]  P. Matthias,et al.  Mapping of the Transcriptional Repression Domain of the Lymphoid-specific Transcription Factor Oct-2A* , 1996, The Journal of Biological Chemistry.

[18]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[19]  T. Ikonen,et al.  Interaction between the Amino- and Carboxyl-terminal Regions of the Rat Androgen Receptor Modulates Transcriptional Activity and Is Influenced by Nuclear Receptor Coactivators* , 1997, The Journal of Biological Chemistry.

[20]  P. Matthias,et al.  Transcriptional activation and repression, two properties of the lymphoid-specific transcription factor Oct-2a. , 1995, European journal of biochemistry.

[21]  R. Tjian,et al.  The cell-type-specific activator region of c-Jun juxtaposes constitutive and negatively regulated domains. , 1992, Genes & development.

[22]  C. Glass,et al.  A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression , 1997, nature.

[23]  Gene regulation by steroid hormones , 1989, Cell.

[24]  B. O’Malley,et al.  Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). , 1992, The Journal of biological chemistry.

[25]  D. Chalbos,et al.  Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. , 1994, The Journal of biological chemistry.

[26]  P. Deininger,et al.  Identification of a New Subclass of Alu DNA Repeats Which Can Function as Estrogen Receptor-dependent Transcriptional Enhancers (*) , 1995, The Journal of Biological Chemistry.

[27]  G. Jenster,et al.  Steroid receptor induction of gene transcription: a two-step model. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[29]  D. McDonnell,et al.  RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. , 1994, The Journal of biological chemistry.

[30]  K. Horwitz,et al.  An N-terminal Inhibitory Function, IF, Suppresses Transcription by the A-isoform but Not the B-isoform of Human Progesterone Receptors* , 1998, The Journal of Biological Chemistry.

[31]  B. O’Malley,et al.  CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Wheeler,et al.  Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. , 1994, Molecular endocrinology.

[33]  D. Edwards,et al.  Characterization and functional properties of the A and B forms of human progesterone receptors synthesized in a baculovirus system. , 1991, Molecular endocrinology.

[34]  D. Edwards,et al.  Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. , 2000, Molecular endocrinology.

[35]  D. Fowlkes,et al.  Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β , 1999, Molecular and Cellular Biology.

[36]  M. Imhof,et al.  Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors. , 1994, Seminars in cancer biology.

[37]  P. Giangrande,et al.  Mapping and Characterization of the Functional Domains Responsible for the Differential Activity of the A and B Isoforms of the Human Progesterone Receptor* , 1997, The Journal of Biological Chemistry.

[38]  D. Edwards,et al.  High-Mobility Group Chromatin Proteins 1 and 2 Functionally Interact with Steroid Hormone Receptors To Enhance Their DNA Binding In Vitro and Transcriptional Activity in Mammalian Cells , 1998, Molecular and Cellular Biology.

[39]  X. Y. Li,et al.  Intramolecular inhibition of activating transcription factor-2 function by its DNA-binding domain. , 1996, Genes & development.

[40]  M. Lazar,et al.  Transcriptional activation and repression by RORalpha, an orphan nuclear receptor required for cerebellar development. , 1997, Molecular endocrinology.

[41]  C. Glass,et al.  Co-activators and co-repressors in the integration of transcriptional responses. , 1998, Current opinion in cell biology.

[42]  S. Rusconi,et al.  Definition of a negative modulation domain in the human progesterone receptor. , 1998, Molecular endocrinology.

[43]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[44]  C. Caskey,et al.  Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. , 1989, Nucleic acids research.

[45]  B. O’Malley,et al.  Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast. , 1992, Molecular endocrinology.

[46]  D. Moore,et al.  Two receptor interacting domains in the nuclear hormone receptor corepressor RIP13/N-CoR. , 1996, Molecular endocrinology.

[47]  K. Horwitz,et al.  The subunit structure of human breast cancer progesterone receptors: characterization by chromatography and photoaffinity labeling. , 1983, Endocrinology.

[48]  P. Chambon,et al.  The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. , 1989, Nucleic acids research.

[49]  H. Gronemeyer,et al.  Transcription activation by estrogen and progesterone receptors. , 1991, Annual review of genetics.

[50]  D. Edwards,et al.  Agonist and antagonists induce homodimerization and mixed ligand heterodimerization of human progesterone receptors in vivo by a mammalian two-hybrid assay. , 1998, Molecular endocrinology.

[51]  B. O’Malley,et al.  Identification of a negative regulatory function for steroid receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  C. Glass,et al.  A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains , 1996, Molecular and cellular biology.

[53]  K. Horwitz,et al.  Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. , 1993, Molecular endocrinology.

[54]  M. Tzukerman,et al.  Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.

[55]  Andrew J. Bannister,et al.  An inhibitor domain in c‐Fos regulates activation domains containing the HOB1 motif. , 1995, The EMBO journal.

[56]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[57]  J. Lipsick,et al.  Carboxy-terminal elements of c-Myb negatively regulate transcriptional activation in cis and in trans. , 1992, Genes & development.

[58]  G. Jenster,et al.  Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. , 1997, Recent progress in hormone research.

[59]  J. Pike,et al.  Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.

[60]  R. Tjian,et al.  Control of c-Jun activity by interaction of a cell-specific inhibitor with regulatory domain δ: Differences between v- and c-Jun , 1990, Cell.

[61]  D. Fowlkes,et al.  Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. , 1999, Molecular and cellular biology.

[62]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[63]  K. Horwitz,et al.  A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. , 1994, Molecular endocrinology.

[64]  S. Schreiber,et al.  Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase , 1997, Cell.